2023 International Congress » Parkinson’s Disease: Pharmacology and Therapy

Meeting: 2023 International Congress

A Parkinson Shoe with Combined Plantar Pressure and Vibratory Stimulation in Parkinson’s Disease Patients with Freezing of Gait: A Randomized Controlled Trial with Plantar Pressure Analysis

W. Phuenpathom, P. Panyakaew, P. Vateekul, D. Surangsrirat, R. Bhidayasiri (Bangkok, Thailand)

Adverse Events of Opicapone Adjunctive Therapy in 60 Consecutive Patients

T. Bo, Y. Hashimoto, T. Ichikawa (Saitama, Japan)

Analysis of levodopa use in patients with Parkinson’s Disease during pregnancy: a systematic review of the last twenty years

R. Albuquerque, E. Almeida, G. Herwig, G. Bolner, G. Maia, G. Mantovani, MF. Felippe, V. Müller (Porto Alegre, Brazil)

Analysis of the therapeutic potential of IkT-148009 in Parkinson’s disease

M. Werner, R. Rush, T. Kelly, S. Singh, S. Kruger, C. Olanow, A. Mcgarry (Atlanta, USA)

Angiotensin II Type 1 (AT1) receptor antagonists as potential candidates for anxiety treatment in Parkinson’s Disease

S. Bordet, L. Grasso, L. Udovin, G. Chevalier, M. Otero-Losada, F. Capani, S. Perez-Lloret (Buenos Aires, Argentina)

Anodal Transcranial Direct Current Stimulation (tDCS) on sensorimotor cortex in patients with early-onset Parkinson’s Disease: a Pilot Study.

C. Simonetta, J. Bissacco, M. Conti, V. Ferrari, M. Pierantozzi, C. Salimei, A. Stefani, NB. Mercuri, T. Schirinzi (Roma, Italy)

Anodal transcranial direct current stimulation could change the metabolomic profiles of cerebrospinal fluid in Parkinson’s disease

W. Jang, H-T. Kim (Gangneung, Republic of Korea)

Assessment of non-motor symptoms of Parkinson’s disease after the repeated courses of the autologous stem cell therapy

V. Chyzhyk, A. Boika, V. Ponomarev (Minsk, Belarus)

Bone Health in Parkinson’s Disease

E. Killeen, C. Gallagher, A. Mcdonough (Dublin, Ireland)

Clinical analysis of Levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease. A single-center retrospective cohort study.

D. Rivero Rodriguez, G. Tabar Comellas, MI. Morales Casado, AM. Diezma Martin, D. Garcia Melendez, M. Ennazeh Elkhaili, N. López Ariztegui (Toledo, Spain)

Clinical Improvement and drastic reduction of Equivalent Dose of Levodopa (LEDD) in an Advanced Parkinson’s Disease Patient after Levodopa/Entacapone/Carbidopa Intestinal Gel (LECIG) Treatment

G. Tabar Comellas, MI. Morales Casado, JC. Segundo-Rodríguez, N. Lopez Ariztegui (Toledo, Spain)

Closed-loop gait improvement in Parkinson’s Disease

P. Kirsch, M. Helbig, S. Baudrexel, C. Kell (Frankfurt am Main, Germany)

Combination COMT inhibitor with Levodopa reduces consumption of vitamin B6

D. Kamiyama, N. Nishikawa, S. Ueno, C. Abe, T. Hatano, N. Hattori (Tokyo, Japan)

Comparative efficacy of pharmacological cognitive treatments in Parkinson’s disease and Dementia of Lewy Bodies: systemic review & network meta-analysis

F. Al Hajraf, S. Manohar, M. Hu (Oxford, United Kingdom)

Computerized assessment of Handwriting in Parkinson’s Disease Before and After Dopaminergic Medication

L. Diaz-Feliz, P. Sanz-Cartagena, M. Faundez-Zanuy, J. Arbelo-Gonzalez, P. Garcia-Ruiz (Las Palmas, Spain)

Continuity and presence of side effects of continuous subcutaneous apomorphine infusion and levodopa-carbidopa intestinal gel infusion in advanced Parkinson’s disease, in a movement disorder unit in Spain

I. Muro Garcia, J. Alonso Maroto, B. Gonzalez Garcia, E. Carabajal Pendon, E. Casas, L. Lopez Manzanares (Madrid, Spain)

Controlled-release zolpidem improves freezing of gait and levodopa-induced dyskinesias in a patient with Parkinson’s disease.

P. Barbosa, E. Fonoff, MG. Ghilardi (Sao Paulo, Brazil)

Correlation between hemoglobin level and disease severity in patients with Parkinson’s disease

O. Gavriliuc, L. Rotaru, M. Gavriliuc, A. Caldarov (Chisinau, Republic of Moldova)

Design of a Phase 2 Study of Suvecaltamide in Moderate to Severe Parkinson’s Disease Tremor

R. Hauser, C. Adler, G. Deuschl, M. Baladi, P. Chandler, T. Skarpass, K. Xu, P. Lewitt (Tampa, USA)

Development of potent, orally bioavailable, and highly selective LRRK2 PROTAC® degrader molecules as potential disease modifying therapeutics for Parkinson’s disease

K. Kelly, J. Meredith, L. Kimmel, S. Sparks, A. Desantis, D. Bryce, R. Wilson, J. Corradi, S. Keenan, G. Cadelina, J. Pizzano, A. Cacace (New Haven, USA)

Development of therapeutic substances for the disassembly of α-synuclein aggregates as disease-modifying treatment of synucleinopathies

A. Willuweit, M. Sevenich, G. Tamgüney, J. Mohrlüder, D. Willbold (Düsseldorf, Germany)

Dyskinesia and adherence to safinamide and opicapone in fluctuating patients with Parkinson’s disease: observational retrospective study

P. Lorenzo-Barreto, I. Pareés, P. Pérez-Torre, S. Fanjul, JL. López-Sendón, F. Pérez-Trapote, A. Sáez-Marín, E. Stiauren-Fernández, á. Patiño-Patón, JC. Martínez-Castrillo, A. Alonso-Cánovas (Madrid, Spain)

Effect and Mechanism of Shaoyao Gancao Decoction(SGD) in Treatment of Pain in Parkinson’s Disease Based on Network Pharmacology and Molecular Docking

Q. Zhao (Shanghai, China)

Effect of differences in stomach and small intestine pH on response to levodopa in patients with Parkinson’s Disease.

M. Arena, B. Brumbach, S. Diamond, K. Block, J. Nutt, R. Pfeiffer, D. Safarpour (Portland, USA)

Effect of intensive Game-based neurorehabilitation (GBNR) on gait, balance and quality of life (QOL) in Parkinson’s patients: A prospective randomized control study

R. Savaj, P. Vengurlekar, C. Sankhla, S. Patel (Mumbai, India)

Effect of variants in COMT and UGT1A genes on clinical response in patients with Parkinson’s disease treated with opicapone

E. Ojeda-Lepe, S. García-Díaz, R. Díaz Belloso, L. Muñoz-Delgado, S. Jesús, MT. Periñán, B. Benítez Zamora, AD. Adarmes-Gómez, D. Macías-García, M. Martín-Bornez, M. Bonilla-Toribio, D. Buiza-Rueda, R. Pineda-Sánchez, F. Carrillo, P. Gómez-Garre, P. Mir (Seville, Spain)

Effectiveness of use of Pictographs on Levodopa packaging to ensure awareness of Levodopa/Carbidopa spacing with meals in patients of Idiopathic Parkinson’s disease.

M. Matta, N. Sawal (Chandigarh, India)

Effects of NE3107 anti-inflammatory treatment on motor activity and neurodegenerative features of Parkinson’s disease in a marmoset monkey model

I. Philippens, C. Ahlem, C. Reading (Antwerp, Belgium)

Effects of Subthalamic Nucleus Deep Brain Stimulation on Phase Amplitude Coupling in Parkinson’s disease

A. Bhattacharya, JF. Nankoo, N. Drummond, K. Udupa, A. Lozano, M. Hodaie, S. Kalia, A. Fasano, R. Munhoz, A. Lang, R. Chen (Toronto, Canada)

Efficacy and safety of adjunctive oral therapy in Parkinson’s disease with motor complications: a systematic review and network meta-analysis

V. Sisodia, L. Dubbeld, RMA. de Bie, GS. Duarte, J. Costa, JM. Dijk (Amsterdam, Netherlands)

Efficacy and safety of safinamide in PD patients over 70 years vs. under 70 years old;

A. Ferreira, M. Rodrigues (Braga, Portugal)

Evaluation of cases of psychosis from opicapone safety data

L. Guedes, I. Peixoto, K. Erb-Zohar, C. Novais, M. Sampaio, C. Santos, J. Graça, V. Vuca, P. Calero, H. Gama (Coronado, Portugal)

Evaluation of neuroprotective role of carvacrol via Nrf2-NLRP3 axis in rotenone induced PD mice model

D. Khatri, S. Shah, K. Tryphena (Hyderabad, India)

Exercise and levodopa metabolism in Parkinson disease

M. Figura, J. Giebułtowicz, A. Mrozowicz, S. Szlufik, D. Koziorowski (Warsaw, Poland)

Factors affecting adaptive deep brain stimulation (aDBS) indications in Parkinson’s disease

J. Tanimura (Matsumoto, Japan)

First Case Series on the use of a High Frequency Vibrotactile Stimulation and Cueing Device in Panama

R. Rodriguez, L. Pinilla, J. Villarreal (Panama, Panama)

Freezing of gait in Parkinson’s disease with glucocerebrosidase mutations: prevalence, clinical correlates and effect on quality of life

R. Ou, C. Li, Q. Wei, K. Liu, J. Lin, T. Yang, Y. Xiao, Q. Jiang, Y. Cheng, Y. Hou, L. Zhang, W. Song, X. Chen, X. Lai, H. Shang (Chengdu, China)

Glucocerebrosidase (GCase) activator, Ambroxol, reduces alpha-synuclein serine-129 phosphorylation and oligomers in mutant LRRK2 R1441G mouse brains

Z. Choi, E. Chang, H. Liu, S. Zhang, Y. Ruan, K. Leung, S. Pang, M. Kung, D. Ramsden, S. Ho, P. Ho (Hong Kong, Hong Kong)

Glunomab: a novel therapeutics for the treatment of Parkinson’s Disease

D. Torrente, E. Su, GP. Schielke, M. Warnock, T. Stevenson, K. Mann, F. Lesept, N. Delétage, M. Blanc, D. Vivien, D. Lawrence (Ann Arbor, USA)

Gluten-free diet in Parkinson’s disease patients – feasibility, safety and preliminary results

H. Brozova, K. Polakova, M. Fialova, T. Gentileova, J. Rusz, D. Funda (Prague, Czech Republic)

GT-02287, a brain-penetrant structurally targeted allosteric regulator for glucocerebrosidase shows evidence of pharmacological efficacy in an animal model of Parkinson’s disease.

B. Calvo-Flores Guzman, N. Perez-Carmona, A. Garcia-Collazo, E. Cubero, X. Barril, M. Bellotto, J. Taylor (Lugano, Switzerland)

Home-based titration with Duodenal infusion of Levodopa in People with Parkinson’s disease: an observational feasibility study

B. Biering-Sørensen, N. Nielsen, A. Isenberg, L. Olsen, M. Javidi, J. Vilhelmsen, M. Møller, M. Olsen, J. Clausen, T. Thomsen (Glostrup, Denmark)

Honey prevented MPTP-induced oxidative stress, neuroinflammation and gliosis in adult male Swiss mice.

F. Sulaimon, R. Ibiyeye, A. Imam, A. Imam, M. Ajao (Ilorin, Nigeria)

Identification of xylopropamine as a potential dopamine D2 receptor agonist through computational drug discovery pipeline

B. Ugbedeojo, P. Adoyi, A. Abah, O. Onimisi, S. Musa, A. Omoniyi (Zaria, Nigeria)

Identification of ZYIL1, a novel NLR family pyrin domain containing 3 protein inhibitor: a potential disease modifier in Parkinson’s disorder

A. Chatterjee (Ahmedabad, India)

Initial 24-hours Levodopa Carbidopa Intestinal Gel initiation in advanced Parkinson’s disease

J. Szász, V. Constantin, K. Orban-Kiss, S. Bataga, L. Bancu, R. Neagoe, J. Szederjesi, M. Ciorba, I. Mihaly, K. Kelemen, S. Szatmari (TARGU MURES, Romania)

Initial clinical experience with levodopa-entacapone-carbidopa intestinal gel infusion (LECIG) for the management of advanced Parkinson´s disease in Croatia

P. Bago Rožanković, S. Lasić, F. Borovečki, S. Telarović, R. Perković, V. Vuletić, O. Perković, V. Rački, S. Tomić (Zagreb, Croatia)

Investigation of superficial brain stimulation (SBS) in Parkinsonian rats as a non-invasive alternative treatment for patients with movement disorders

G. Weistroffer, J. Blagg, M. Tashli, R. Hadimani, D. Kumbhare, M. Baron (Richmond, USA)

Istradefylline therapy for PD plus oromandibular dystonia

NAO. Kanzato, SAT. Mochizuki (Haearu-cho, Okinawa, Japan)

Levodopa Carbidopa Intestinal Gel for Parkinson’s Disease over 11 years: A Single Center “Real-World” Experience

C. Vekhande, M. Hamed, G. Tremain, J. Mah, A. Shetty, A. Lazarescu, O. Suchowersky (Edmonton, Canada)

Levodopa-carbidopa intestinal gel for managing severe refractory tremors of idiopathic Parkinson’s disease: Case Series

M. Abu Al-Melh, N. Abdelall, T. Al-Otaibi (Ahmadi governorate, Kuwait)

Levodopa-Entacapone-Carbidopa Intestinal Gel in advanced Parkinson’s disease: a single center experience

V. Constantin, S. Szatmari, K. Orban-Kis, S. Bataga, R. Neagoe, M. Ciorba, I. Mihaly, K. Kelemen, J. Szasz (Targu Mures, Romania)

Levodopa-entacapone-carbidopa intestinal gel infusion for Parkinson’s disease: An analysis of data collected from the Swedish national register of Parkinson’s disease.

M. öthman, P. Odin, F. Bergquist, A. Johansson, R. Constantinescu, M. Scharfenort, H. Widner, D. Nyholm (Uppsala, Sweden)

Levodopa-entacapone-carbidopa-infusion treatment in Parkinson’s disease: A six-month follow-up study

V. Viljaharju, T. Mertsalmi, KAM. Pauls, M. Koivu, J. Eerola-Rautio, M. Udd, E. Pekkonen (Helsinki, Finland)

Levodopa-induced orthostatic hypotension in parkinsonism: a red flag of autonomic failure

I. Cani, P. Guaraldi, G. Giannini, L. Sambati, G. Barletta, P. Cortelli, G. Calandra-Buonaura (Bologna, Italy)

Local field potentials can guide programming of Deep Brain Stimulation in Parkinson’s Disease

B. Seegmiller, P. Coss (San Antonio, USA)

Long duration response to levodopa in advanced Parkinson disease

P. Nieto, A. García, I. Martín, R. Ibañez, JP. Cabello, J. Vaamonde (Ciudad Real, Spain)

LRRK2 Inhibition by BIIB122/DNL151 Demonstrates Robust Target and Lysosomal Engagement: Pharmacokinetics, Pharmacodynamics and Safety in Phase 1 and Phase 1b Studies in Healthy and Parkinson’s Participants

S. Dhuria, P. Roychowdhury, H. Wong, S. Huntwork-Rodriguez, H. Solanoy, M. Goo, R. Maciuca, O. Mabrouk, K. Fraser, K. Scearce-Levie, D. Graham, D. Jennings, M. Troyer (South San Francisco, USA)

LRRK2 kinase activity regulates sphingolipid hydrolase enzymatic activities in different cell lines: induced pluripotent stem cell-derived dopaminergic neurons, primary monocyte‐derived macrophages and SH-SY5Y

T. Usenko, K. Basharova, A. Bezrukova, A. Izyumchenko, M. Nikolaev, G. Baydakova, S. Pavlova, E. Grigorieva, S. Medvedev, E. Zakharova, S. Zakian, S. Pchelina (Gatchina, Russian Federation)

LRRK2 PROTAC® degrader molecules induce robust biomarker responses in preclinical in vivo pharmacology studies following acute and chronic oral dosing

J. Meredith Jr, K. Kelly, V. Guss, A. Desantis, L. Kimmel, S. Soletsky, J. Pizzano, G. Cadelina, J. Chavez, S. Sparks, A. Cacace (New Haven, USA)

modulation of sodium potassium ATPase activity by norepinepherine and serotonin to find an effective cure of parkinson’s disease by introducing the novel concept of insilico drug repurposing

S. Sinha (Prayagraj, India)

Motor complications in Parkinson’s disease

S. Gandhi, T. Zerenner, A. Nodehi, M. Lawton, K. Grosset, V. Marshall, F. Al-Hajraf, Y. Ben-Shlomo, M. Hu, D. Grosset (Glasgow, United Kingdom)

Multiple N-of-1 trials to investigate hypoxia-based treatment in Parkinson’s disease: safety and short-term effects

J. Janssen Daalen, M. Meinders, F. Giardina, S. Mathur, P. Ainslie, D. Thijssen, B. Bloem (Nijmegen, Netherlands)

NLX-112 has favorable safety and tolerability and displays efficacy against levodopa-induced dyskinesia (LID) in Parkinson’s disease (PD)

P. Svenningsson, P. Odin, F. Berquist, K. Wirdefeldt, D. Nyholm, M. Andréasson, I. Markaki, A. Johansson, M. Jergil, C. Jankosky, M. Varney, F. Herbrecht, S. Johnson, A. Newman-Tancredi (Solna, Sweden)

Observations on 5 Parkinson’s patients taking Mucuna pruriens as natural source of levodopa

S. Elsas (Arlesheim, Switzerland)

On-demand therapy (ODT) in Parkinson’s disease: a survey of advanced practice providers

K. Papesh, A. Merriam, C. Zebendon (Phoenix, USA)

Opicapone versus entacapone: Head-to-head comparison of Healthcare Resource Utilisation in COMT-I naïve People with Parkinson’s

G. Harrison-Jones, L. Marston, F. Morgante, K R. Chaudhuri, G. Castilla-Fernández, V. Di Foggia (Windsor, United Kingdom)

Patterned alternating-coloured strips for freezing of gait – Novel solution for a disabling symptom.

M. Matta, N. Sawal, D. Bansal (Chandigarh, India)

Pharmacological combinations in early stages of Parkinson’s disease and association with motor complications

A. Lanore, E. Januel, N. Bertille, P. Menon, Y. Rajasegaram, S. Carvalho, LL. Mariani, M. Fabbri, O. Rascol, F. Tubach, Y. de Rycke, JC. Corvol (Paris, France)

Pisa syndrome and botulinum toxin injection in paraspinal muscles ipsilateral to the bending side: a pilot study

V. Cenacchi, TMI. Lombardo, G. Bellavita, M. Catalan, V. Tommasini, M. Liccari, G. Mazzon, L. Antonutti, P. Manganotti (Trieste, Italy)

Pre-operative predominance of Tremor versus PIGD scores in drug OFF state predicts motor and non-motor outcomes of STN-DBS for Parkinson’s disease

C. Nagireddy, K. Pillai, S. Joshua, A. Pnair, D. Panikar, M. Chacko, A. Kishore (Kochi, India)

Predicting motor outcome and quality of life after subthalamic DBS for Parkinson’s Disease: the role of standard screening measures and wearable-data

V. Geraedts, J. van Vugt, J. Marinus, R. Kuiper, H. Middelkoop, R. Zutt, N. vd Gaag, C. Hoffmann, L. Dorresteijn, J. van Hilten, MF. Contarino (Leiden, Netherlands)

Real-World Utilization of Istradefylline Among Patients with Parkinson’s Disease

M. Rezak, J. Qian, Y. Zhao, A. Silverstein, J. Chamber, J. Swindle, N. Kronfeld, P. Lewitt (Hoffman estates, USA)

Response of extraocular movements in parkinson’s disease to levodopa: an electrooculographic perspective

S. Patel, C. Sankhla, R. Savaj (Mumbai, India)

Response to Levodopa in Parkinson´s Disease Over Time. A 4-year Follow-up Study.

D. Santos García, T. de Deus, C. Cores, M. Feal Painceiras, I. García-Díaz, M. íñiguez, J. Paz González, S. Jesús, M. Cosgaya, J. García Caldentey, N. Caballol, I. Legarda, J. Hernández Vara, I. Cabo, L. López Manzanares, I. González Aramburu, M. Avila, V. Gómez Mayordomo, V. Nogueira, J. Dotor, C. Borrué, B. Solano, M. álvarez Sauco, L. Vela, F. Escalante, E. Cubo, Z. Mendoza, J. Martínez Castrillo, P. Sánchez Alonso, M. Alonso Losada, N. López Ariztegui, M. Gastón, J. Kulisevsky, M. Seijo, C. Valero, R. Alonso Redondo, M. Buongiorno, C. Ordás, P. Martínez Martín, P. Mir, C. Coppadis (A Coruña, Spain)

Retrospective exploration of the 5-2-1 criteria in clinical practice

M. Karlstedt, A. Johansson (Stockholm, Sweden)

SAFE-DBS – A monocentric, randomised, blind evaluation of safinamide in the perioperative period in Parkinsonian patients with deep brain stimulation

E. Gülke, M. Höfs, H. Pinnschmidt, A. Gulberti, C. Moll, U. Hidding, C. Buhmann, M. Heise, W. Hamel, M. Pötter-Nerger (Hamburg, Germany)

Safety in Levodopa/carbidopa Intestinal Gel (LCGI) titration in the Intensive Care Unit (ICU) setting for Parkinson’s Disease (PD) patient with severe dysphagia

N. Lopez Ariztegui, G. Tabar Comellas, MI. Morales Casado, D. Rivero Rodriguez, M. Ennazeh, P. Leal Sanz (Toledo, Spain)

Safinamide in Parkinson´s Disease. A retrospective study

M. Carmona-Abellan, M. Erburu, A. Cabrera, C. Garcia-Monco, K. Berganzo, B. Huete (Bilbao, Spain)

Screening and Treatment of Depression in Parkinson’s Disease Within Movement Disorders Centers

C. Marras, D. Weintraub, J. Beck, A. Naito, Z. Meyer, N. Dahodwala, T. Davis, K. Mills, J. Miyasaki, S. Mantri, M. Neault, A. Brown, A. Allen, E. Nelson, H. Liu (Toronto, Canada)

Sex differences for off episodes in Parkinson’s disease

A. Ratnavel, C. Jiang, A. Liu, K. Wang, A. Tsai, K. Wyman-Chick, E. Bayram (La Jolla, USA)

Sex differences in motor response to levodopa in early Parkinson’s disease

M. Gevertzman, A. Hooyman, J. Longhurst, M. Landers (Las Vegas, USA)

Sport based approach in patients with Parkinson’s disease

G. Peker (CABA, Argentina)

Testing the applicability of the dysarthria analyzer to detect levodopa effects on speech in a German cohort of people with Parkinson’s disease

T. Thies, J. Schreen, H. Jergas, M. Barbe (Cologne, Germany)

The effect of continuous subcutaneous apomorphine infusion on vitamin B metabolites and plasma homocysteine in Parkinson’s disease patients

O. Phokaewvarangkul, N. Kantachadvanich, R. Bhidayasiri (Bangkok, Thailand)

The effect of taVNS on gait in advanced Parkinsons disease – a double blind, sham controlled motion sensors study in 30 patients

V. van Midden, Z. Pirtošek, U. Simončič, M. Kojović (Ljubljana, Slovenia)

The efficacy of dopamine agonists or monoamine oxidase type B inhibitors as monotherapy in patients with early Parkinson disease: A network meta-analysis

CSC. Chuang (Changhua, Taiwan)

The induction of mitochondrial damage by alpha synuclein In Parkinson’s disease.

B. Adebisi (osogbo, Nigeria)

The mGlu2 positive allosteric modulator AZD8529 alleviates L-DOPA-induced dyskinesia and psychosis-like behaviours in the parkinsonian marmoset

J. Shaqfah, I. Frouni, C. Kwan, D. Bédard, S. Nuara, J. Gourdon, A. Hamadjida, P. Huot (Montreal, Canada)

The Short Duration Response and Long Duration Response to L-Dopa are Needed to Restore Vigor-Motivation Coupling in Parkinson Disease

J. Brissenden, T. Scerbak, R. Albin, T. Lee (Ann Arbor, USA)

The specific application of a motor rehabilitation package in correcting the psycho-emotional sphere in patients with Parkinson’s disease.

N. Voloshyna, I. Bogdanova, I. Voloshyn-Haponov (Kharkiv, Ukraine)

Therapeutic effects of citral nanoliposome on Parkinson’s treatment in a rat model: Modulation via neurochemical, inflammatory and antioxidant pathways

N. Moradikor, M. Haghipanah, W. Mohamed (Tbilisi, Georgia)

Thymoquinone and Edible Bird Nest: The Secret Ingredients to Protect Against MPTP-induced zebrafish Parkinson’s disease

W. Mohamed (Kuantan, Malaysia)

Tremor characteristics differentially respond to levodopa and subthalamic nucleus deep brain stimulation in Parkinson’s disease

T. Wirth, F. Ferreira, N. Vijiaratnam, C. Girges, A. Pakzad, A. Roquemaurel, O. Sinani, J. Hyam, M. Hariz, L. Zrinzo, H. Akram, P. Limousin, T. Foltynie (Strasbourg, France)